|
May 12
|
Valneva’s chikungunya vaccine use halted in older adults amid safety concerns
|
|
May 12
|
Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States
|
|
May 9
|
Eli Lilly extends Purdue alliance; EMA investigates Valneva shot
|
|
May 8
|
Valneva SE (INRLF) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Operational ...
|
|
May 7
|
VALNEVA Declaration of shares and voting rights: April 30, 2025
|
|
May 7
|
Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly
|
|
May 7
|
Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates
|
|
Apr 10
|
VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study
|
|
Apr 9
|
Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2
|
|
Apr 8
|
Exploring Three High Growth Tech Stocks In Europe
|
|
Jan 3
|
VALNEVA Declaration of shares and voting rights: December 31, 2024
|
|
Oct 4
|
Valneva SE - Declaration of shares and voting rights - September 30, 2024
|
|
Oct 3
|
Valneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ET
|
|
Aug 6
|
VALNEVA - Declaration of shares and voting rights: July 31, 2024
|
|
Jul 26
|
Can Valneva (VALN) Climb 149.04% to Reach the Level Wall Street Analysts Expect?
|
|
Jun 24
|
Valneva's (VALN) CHIKV Vaccine Gets Health Canada's Approval
|
|
Jun 24
|
Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ®
|
|
Jan 10
|
Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine
|
|
Dec 29
|
Valneva Provides Updated 2023 Financial Guidance
|
|
Dec 20
|
Valneva Shareholders Approve EGM Resolutions Including the Transition to a Board of Directors
|